


Iovance IP Leadership Within T-cell Based Immunotherapy

Iovance IP Portfolio Summary:

- >60 granted or allowed US and international patents
- Compositions of matter for TIL products
- Methods of treatment in a broad range of cancers
- Manufacturing processes
- >700 patents and applications worldwide, including major pharmaceutical markets
- Gen 2 patent rights expected to provide exclusivity into 2038
- Additional patent rights expected to provide exclusivity into 2042

We established our leadership within T cell-based immunotherapy by building and augmenting the patent rights for our proprietary tumor infiltrating lymphocyte (TIL) technology platform—developed internally and licensed from third parties.



Broad, Iovance-Owned IP Around AMTAGVI™ And Other TIL Therapy In Development



Iovance's patent portfolio also includes patents and patent applications relating to:

- Frozen tumor-based TIL technologies;
- Remnant TIL and digest TIL compositions and methods;
- Use of co-stimulatory and T cell modulating molecules in TIL therapy and manufacturing;
- Stable and transient genetically-modified TIL therapies;
- Methods of using immune checkpoint inhibitors in combination with TIL therapies;
- TIL selection technologies;
- Methods of treating patient subpopulations.

Iovance owns at least 60 U.S. patents related to TIL therapy, including patents directed to compositions and methods of treatment in a broad range of cancers, such as U.S. Patent Nos. 10,130,659; 10,166,257; 10,272,113; 10,363,273; 10,398,734; 10,420,799; 10,463,697; 10,517,894; 10,537,595; 10,639,330; 10,646,517; 10,653,723; 10,695,372; 10,894,063; 10,905,718; 10,918,666; 10,925,900; 10,933,094; 10,946,044; 10,946,045; 10,953,046; 10,953,047; 11,007,225; 11,007,226; 11,013,770; 11,026,974; 11,040,070; 11,052,115; 11,052,116; 11,058,728; 11,083,752; 11,123,371; 11,141,438; 11,168,303; 11,168,304; 11,179,419; 11,202,803; 11,202,804; 11,220,670; 11,241,456; 11,254,913; 11,266,694; 11,273,180; 11,273,181; 11,291,687; 11,304,979; 11,304,980; 11,311,578; 11,337,998; 11,344,579; 11,344,580; 11,344,581; 11,351,197; 11,351,198; 11,351,199; 11,364,266; 11,369,637; 11,384,337; 11,433,097; 11,517,592; 11,529,372; 11,541,077; 11,713,446; 11,819,517; and 11,866,688.

Iovance also owns U.S. patents covering methods of manufacturing TIL and TIL manufactured from a tumor digest and the use thereof, such as U.S. Patent Nos. 11,007,225; 11,007,226; 11,052,115; 11,052,116; 11,058,728; 11,083,752; 11,123,371; 11,141,438; 11,179,419; 11,202,803; 11,202,804; 11,241,456; 11,254,913; 11,266,694; 11,273,180; 11,273,181; 11,291,687; 11,304,979; 11,304,980; 11,337,998; 11,344,579; 11,529,372; 11,541,077; and others. U.S. Patent No. 11,058,728 specifically covers a method of treatment using expanded TILs manufactured from a tumor digest where the expansion steps through the step of cryopreservation of the infusion bag having a harvested TIL population are performed within about 24 days. U.S. Patent No. 11,123,371 specifically covers a cryopreserved TIL composition comprising expanded TILs manufactured from a cryopreserved tumor digest where the expansion steps through the step of cryopreservation of the infusion bag having a harvested TIL population are performed within about 24 days. U.S. Patent No. 11,141,438 specifically covers an expanded population of TILs manufactured from a cryopreserved tumor digest where the expansion steps through the harvest step are performed within about 24 days. U.S. Patent No. 11,179,419 specifically covers a method for expanding TILs from a cryopreserved tumor digest where the expansion steps through the step of cryopreservation of the infusion bag having a harvested TIL population are performed within about 24 days.

Iovance owns U.S. Patent No. 11,819,517 covering methods of using TIL for the treatment of double refractory melanoma in a patient resistant to a PD1 or PD-L1 inhibitor and resistant to a BRAF inhibitor or a BRAF inhibitor and a MEK inhibitor, which methods are free of any TIL process limitations.

Iovance owns U.S. Patent No. 11,384,337 covering methods of manufacturing gene-edited TILs, which methods are free of gene-editing process and target limitations.

Iovance owns U.S. Patent No. 11,713,446 covering methods of manufacturing TIL modified to effect transient alteration of expression of one or more proteins.

Iovance owns U.S. patents covering the use of the combination of TIL therapy and an anti-PD-1 antibody, such as U.S. Patent No. 10,272,113, or an anti-PD-L1 antibody, such as U.S. Patent No. 11,013,770.

Iovance holds an exclusive license under patents and patent applications of Novartis covering Iovance's IOV-3001 product.

Iovance holds an exclusive license under patents and patent applications of Cellectis covering Iovance's IOV-4001 product.

U.S. Patent/Application Information for Iovance Products:

Therapy	Pursued Indication	Composition of Matter	Method of Use	Method of Manufacturing	
AMTAGVI™	Patients with metastatic melanoma	US 10,894,063; US 10,398,734; US 10,537,595; US 10,695,372; US 10,653,723; US 11,337,998; US 11,344,579	US 10,166,257; US 10,272,113; US 10,463,697; US 10,905,718; US 10,925,900; US 10,933,094; US 10,946,044; US 10,946,045; US 10,953,046;	US 10,953,047; US 11,202,803; US 11,202,804; US 11,241,456; US 11,273,181; US 11,433,094; US 11,517,592; US 11,819,517	US 10,420,799; US 10,639,330; US 10,918,666; US 11,273,180; US 11,291,687; US 11,304,979
Lifileucel	Patients with NSCLC	US 10,894,063; US 10,398,734; US 10,537,595; US 10,653,723; US 10,695,372; US 11,337,998; US 11,344,579	US 10,166,257; US 10,272,113; US 10,463,697; US 10,905,718; US 10,933,094; US 10,946,044; US 10,946,045;	US 10,953,046; US 10,953,047; US 11,202,804; US 11,241,456; US 11,273,181; US 11,433,097	US 10,420,799; US 10,639,330; US 10,918,666; US 11,168,304; US 11,273,180; US 11,291,687; US 11,304,979
Lifileucel	Patients with HNSCC or cervical cancer	US 10,894,063; US 10,398,734; US 10,537,595; US 10,653,723; US 10,695,372; US 11,337,998; US 11,344,579; US 11,376,318 (NIH)	US 10,130,659; US 10,166,257; US 10,272,113; US 10,463,697; US 10,363,273; US 10,905,718; US 10,933,094; US 10,946,044; US 10,946,045; US 10,953,046;	US 10,953,047; US 11,202,804; US 11,241,456; US 11,273,181; US 11,433,097; US 11,077,182 (NIH); US 11,331,385 (NIH); US 11,338,032 (NIH); US 11,376,318 (NIH)	US 10,420,799; US 10,639,330; US 10,918,666; US 11,273,180; US 11,291,687; US 11,304,979
IOV-4001 (PD1 KO TIL)	Patients with metastatic melanoma or NSCLC	US 10,537,595; US 10,653,723	US 10,905,718; US 10,933,094; US 10,946,044; US 10,946,045;	US 10,953,046; US 10,953,047; US 11,202,804; US 11,819,517	US 11,304,979; US 11,674,155 (Cellectis); US 11,891,614 (Cellectis)
IOV-3001 (Next-Generation IL-2)	Supportive therapy for patients treated with TIL	WO 2018/215936A1 (Novartis) US 2020/270334A1 (Novartis)	WO 2018/215936A1 (Novartis) US 2020/270334A1 (Novartis)	WO 2018/215936A1 (Novartis) US 2020/270334A1 (Novartis)	
IOV-2001 (PBL)	Patients with CLL or SLL	WO 2020/180733 A1; US 2020/0224161 A1; US 2020/0347350 A1	WO 2020/180733 A1; US 2020/0224161 A1; US 2020/0347350 A1	WO 2020/180733 A1; US 2020/0224161 A1; US 2020/0347350 A1	

Abbreviations: CLL, chronic lymphocytic leukemia; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small-cell lung cancer; PBL, peripheral blood lymphocytes; SLL, small lymphocytic leukemia; TIL, tumor infiltrating lymphocytes.